# Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Source: https://onco.cc/trials/nct07008703/  
OnCo record `nct07008703` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Injection of humanized nerve growth factor (NGF) antibody in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.

## Summary

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain is a phase 1/2 interventional study registered as NCT07008703 by Shenyang Sunshine Pharmaceutical Co., LTD., with 132 participants planned, started 2024-03-27 and due to reach its primary completion in 2025-12. Interventions recorded: Injection of humanized nerve growth factor (NGF) antibody.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07008703
- Phase: 1/2
- Setting: Phase Ib/IIa Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of SSS40 in Subjects With Moderate to Severe Bone Metastasis Cancer Pain
- Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT07008703: https://clinicaltrials.gov/study/NCT07008703

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07008703.json